By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion today announced that total revenues in the third quarter were down 23 percent year over year despite an 81 percent uptick in product revenues.

The company also said that it has purchased "substantially all" of the assets of Correlogic Systems, a company currently in Chapter 11 bankruptcy protection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.